Ulinastatin offers protection and, helps functional recovery internal organs in post AMI cardiogenic shock:; a clinical observation.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800020367

Enrollment

Unknown

Registered

2018-12-25

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiogenic shock

Interventions

Ulinastatin group:Ulinastatin treatment

Control group:Routine treatment

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: Selection criteria: patients who meet the American Heart Association and American Heart Association AMI diagnostic criteria and have pump function killips grade 4 have definite symptoms of insufficient blood flow, such as cold skin, cyanosis, oliguria, fast heart rate, weak pulse, low blood pressure (systolic pressure drops below 10.6kPa), low pulse pressure (below 2.7kPa), indifferent expression, slow response, and vague consciousness. Hemodynamic monitoring indicated that the heart index decreased and the left ventricular end diastolic pressure increased, and other corresponding hemodynamic abnormalities.

Exclusion criteria

Exclusion criteria: Exclusion criteria: mechanical complications and death within 24 hours.

Design outcomes

Primary

Measure	Time frame
TNF-a;IL-6;CTnI;BNP;P(A-a)O2;LAC;ST-2;ALT;AST;	—

Countries

China

Contacts

Public ContactHuang Ri-hong

The First Affiliated Hospitol of Dalian Medical University

dl_hrh@163.com+86 18098875857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026